ReviewJournal of orthopaedics
Integration of denosumab therapy in the management of giant cell tumors of bone.
Review in Journal of orthopaedics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- Acetabular Giant Cell Tumor Presenting with Protrusio Acetabuli: A Rare Case Report.Journal of orthopaedic case reports · 2026Article
- Review
- New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.Molecules (Basel, Switzerland) · 2021Review
- A Comparison of the Clinical and Radiological Extent of Denosumab (XgevaJournal of clinical medicine · 2021Article
- The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone.World journal of surgical oncology · 2021Article
- A giant cell tumor of the bone in the rib cage left to proliferate unfettered for seven years to an extensive size.Respiratory medicine case reports · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.